MyJournals Home  

RSS FeedsWeekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines - a phase II multipractice study (BMC Cancer)

 
 

4 may 2012 18:05:05

 
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines - a phase II multipractice study (BMC Cancer)
 




Background: The 3 weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combination chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially in the palliative setting. The present trial examined the efficacy and safety of weekly paclitaxel over a limited duration combined with continued trastuzumab in HER2+ patients. Methods: Patients with histologically confirmed metastatic breast cancer overexpressing HER2 were eligible if pretreated with anthracycline in either the adjuvant or palliative setting. Treatment consisted of weekly trastuzumab (2 mg/kg/week for up to one year after a loading dose of 4 mg/kg in week 1) and paclitaxel (90 mg/m^2, administered in weeks 1-6 and 8-13). Results: Twenty-seven German centers enrolled 121 patients. The median number of metastatic sites was two (range 1-5); 38% of patients had received chemotherapy for advanced disease. After a median 42 weeks of trastuzumab treatment, limited by disease progression in roughly half the patients, a best objective response rate (complete response + partial response) of 76% was achieved, including complete remissions in 29%. 74% of patients lived without tumor progression at six months. Median progression-free and overall survival were 9.4 (95% confidence interval [CI]: 8.1-11.3) and 22 months (95% CI: 17-46). After alopecia, Common Toxicity Criteria grade >=2 toxicity was predominantly hematological (leukopenia [31%] and anemia [41%]); however, thrombocytopenia occurred in only 5%. Neurotoxicity was remarkably low. Two cardiac events (grades 2 and 3) were presumed treatment-related. Conclusions: Weekly paclitaxel plus trastuzumab allows an increased dose density and offers an attractive and effective alternative to the conventional schedule. Limiting the duration of cytotoxic therapy to 3 months seems to be an option to reduce neurotoxicity without impairing long-term outcome.Retrospective Trial Registration: ClinicalTrials.gov NCT01423695


Del.icio.us Digg Facebook Google StumbleUpon Twitter
 
104 viewsCategory: Oncology
 
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model (BMC Cancer)
CENP-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer (Breast Cancer Research)
 
 

The articles that are most similar to this article

 
6.68 04-05-2012 18:35:03 Design of the study: How can health care help female breast cancer patients r... (BMC Cancer)
6.33 04-05-2012 18:11:06 CENP-A, an essential centromere protein, is a prognostic marker for relapse ... (Breast Cancer Research)
2.63 04-05-2012 11:34:19 Osteoblast-secreted collagen upregulates paracrine Sonic hedgehog signaling ... (Molecular Cancer)
1.24 04-05-2012 17:53:54 Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocel... (BMC Cancer)
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:

Oncology

Use these buttons to bookmark us:
Del.icio.us Digg Facebook Google StumbleUpon Twitter


Valid HTML 4.01 Transitional
Copyright © 2008 - 2014 Tim Hulsen, design by Indigonet Services B.V.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn Appartement Nijmegen Residence in France
Indigonet Services BV is not responsible for any incorrect or outdated information on this site.